Copyright
©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Jul 8, 2016; 8(19): 796-814
Published online Jul 8, 2016. doi: 10.4254/wjh.v8.i19.796
Published online Jul 8, 2016. doi: 10.4254/wjh.v8.i19.796
Assembly and release of infectious hepatitis C virus involving unusual organization of the secretory pathway
Miriam Triyatni, Roche Innovation Center, Roche Pharma Research and Early Development, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
Miriam Triyatni, Edward A Berger, Bertrand Saunier, Molecular Structure Section, Laboratory of Viral Diseases, NIAID, NIH, Bethesda, MD 20892-3210, United States
Bertrand Saunier, Unité de Virologie Structurale, Institut Pasteur and CNRS UMR 3569, 75724 Paris, France
Author contributions: Triyatni M designed and performed experiments and analyzed the data; Berger EA provided facilities and resources for research, analyzed the data, and contributed to editing the manuscript; Saunier B designed most and performed some experiments, analyzed the data and wrote the manuscript.
Supported by Intramural Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases (Project No. 1 ZIA AI000733-15: Enveloped Virus Glycoprotein/Receptor Interactions) to Edward A Berger, PhD (MSS, LVD, DIR, NIAID); and ORISE Senior Fellow award (Award No. 1238-1238-03: Department of Energy/Oak Ridge Institute for Science and Education) to Bertrand Saunier, MD, PhD.
Institutional review board statement: Approved the use of serum IgG of a patient cured from an HCV infection for in vitro studies (Hôpital and Institut Cochin, Paris).
Institutional animal care and use committee statement: Not applicable.
Conflict-of-interest statement: Saunier B, Triyatni M and Berger EA are co-inventors on NIH-owned patent #US 9052321 B2 on the HCV particle production system.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Bertrand Saunier, MD, PhD, Unité de Virologie Structurale, Institut Pasteur and CNRS UMR 3569, Centre François Jacob, 28 rue du Docteur Roux, 75724 Paris, France. bsaunier@pasteur.fr
Telephone: +33-01-45688855 Fax: +33-01-45688993
Received: January 31, 2016
Peer-review started: February 1, 2016
First decision: March 25, 2016
Revised: May 16, 2016
Accepted: June 1, 2016
Article in press: June 3, 2016
Published online: July 8, 2016
Processing time: 156 Days and 11.9 Hours
Peer-review started: February 1, 2016
First decision: March 25, 2016
Revised: May 16, 2016
Accepted: June 1, 2016
Article in press: June 3, 2016
Published online: July 8, 2016
Processing time: 156 Days and 11.9 Hours
Core Tip
Core tip: Our system for production of authentic infectious hepatitis C virus (HCV) in non-humanized, non-hepatic cells involves the rearrangement of inner cellular membranes triggered by the replication of flaviviruses. The present results suggest that this feature relies on the re-wiring of host factors that usually contribute to the secretion of glycoproteins to generate an unusual secretory pathway. This model offers a new way to study the properties of free HCV particles, i.e., independently from lipoproteins.